4E Therapeutics

Austin, Texas

Oncologysmall moleculePhase I

What changed

Phase I trial registered: A Study to Assess Safety, Tolerability and Exposure of 4ET1103 in Healthy Human Volunteers

2mo agoTrial registeredMay 14, 2026Source filing (opens the source filing in a new tab)

Momentum

71no change

Accelerating: several high-weight events landed recently.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase I

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
S10 · $349k · non-dilutive
May 15, 2025
PROVIDENCE COLLEGE · PI MILLER, KRISTI E · OD · award ends May 14, 2026 · Spinning Disk Confocal Microscope System
NIH RePORTER · NIH RePORTER 11100415 (opens the source filing in a new tab)
Trial
PHASE1 registered
Apr 18, 2025
Neuropathic Pain · COMPLETED · sponsor: 4E Therapeutics · A Study to Assess Safety, Tolerability and Exposure of 4ET1103 in Healthy Human Volunteers
ClinicalTrials.gov · NCT07586514 (opens the source filing in a new tab)
Grant
R01 · $154k · non-dilutive
Jan 1, 2025
EMORY UNIVERSITY · PI MILLER, KYLE M · NCI · award ends Mar 31, 2028 · Shaping DNA Damage Response Networks Via Histone H2A Variants
NIH RePORTER · NIH RePORTER 11258303 (opens the source filing in a new tab)
Grant
R01 · $378k · non-dilutive
Jan 1, 2025
EMORY UNIVERSITY · PI MILLER, KYLE M · NCI · award ends Mar 31, 2028 · Shaping DNA Damage Response Networks Via Histone H2A Variants
NIH RePORTER · NIH RePORTER 11056120 (opens the source filing in a new tab)
Grant
R01 · $608k · non-dilutive
Aug 6, 2024
MASSACHUSETTS GENERAL HOSPITAL · PI MILLER, KAREN K · NICHD · award ends Apr 30, 2029 · Romosozumab as an adjunct to physiologic estrogen replacement in adolescents and young adults with functional hypothalamic amenorrhea
NIH RePORTER · NIH RePORTER 11162285 (opens the source filing in a new tab)
Grant
R01 · $732k · non-dilutive
May 18, 2021
UNIVERSITY OF SOUTHERN CALIFORNIA · PI COCKBURN, MYLES G · NCI · award ends Apr 30, 2027 · Identifying modifiable factors that reduce the burden of late stage melanoma in Hispanics
NIH RePORTER · NIH RePORTER 11136507 (opens the source filing in a new tab)
Grant
R37 · $559k · non-dilutive
Mar 1, 2021
UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILLER, KIMBERLY ANN · NCI · award ends Feb 28, 2026 · Social Health, Activity Behaviors, and Quality of Life among Young Adult Cancer Survivors: A Longitudinal Study
NIH RePORTER · NIH RePORTER 11046632 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator MILLER, KYLE M is named on this company's filings"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator MILLER, KAREN K is named on this company's filings"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
new_entity links the trial record at 0.22{"reasons":["no candidate cleared the review threshold"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

Phase I trial registered: A Study to Assess Safety, Tolerability and Exposure of 4ET1103 in Healthy Human Volunteers
2mo agoTrial registeredSource (opens the source filing in a new tab)
Trial completed: A Study to Assess Safety, Tolerability and Exposure of 4ET1103 in Healthy Human Volunteers
2mo agoTrial completedSource (opens the source filing in a new tab)
NIH S10 · $0.3M · Spinning Disk Confocal Microscope System
May 2025New grantSource (opens the source filing in a new tab)
NIH R37 · $0.6M · Social Health, Activity Behaviors, and Quality of Life among Young Adult Cancer Survivors: A Longitudinal Study
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Identifying modifiable factors that reduce the burden of late stage melanoma in Hispanics
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.4M · Shaping DNA Damage Response Networks Via Histone H2A Variants
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · Romosozumab as an adjunct to physiologic estrogen replacement in adolescents and young adults with functional hypothalamic amenorrhea
Apr 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.2M · Shaping DNA Damage Response Networks Via Histone H2A Variants
Mar 2025Grant renewalSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

S10 · $349k · non-dilutive

PHASE1 registered

R01 · $154k · non-dilutive

R01 · $378k · non-dilutive

R01 · $608k · non-dilutive

R01 · $732k · non-dilutive

R37 · $559k · non-dilutive